European Journal of Heart Failure最新文献

{"title":"Reply to 'Beyond pharmacotherapy: Addressing system-level barriers in women's heart failure care'.","authors":"Guillaume Baudry,Ouarda Pereira,François Roubille,Nicolas Girerd","doi":"10.1002/ejhf.3793","DOIUrl":"https://doi.org/10.1002/ejhf.3793","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study'.","authors":"Jan Biegus,Piotr Ponikowski","doi":"10.1002/ejhf.3792","DOIUrl":"https://doi.org/10.1002/ejhf.3792","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"89 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure","authors":"Tibor Kempf, Welf Geller, Jan Fuge, Mircea‐Andrei Sandu, Marius M. Hoeper, Roman Pfister, Sascha Macherey‐Meyer, Stefan Störk, Daniel Scheiber, Jürgen Bogoviku, Jörn Tongers, Tarek Bekfani, Christoph Schindler, Dominik Berliner, Udo Bavendiek, Johann Bauersachs","doi":"10.1002/ejhf.3789","DOIUrl":"https://doi.org/10.1002/ejhf.3789","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"675 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’","authors":"Jan Biegus, Robert Zymliński, Piotr Ponikowski","doi":"10.1002/ejhf.3773","DOIUrl":"https://doi.org/10.1002/ejhf.3773","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"51 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS.","authors":"Antoni Bayes-Genis,Anping Cai,Yuxi Liu,Ambarish Pandey,Rodica Pop-Busui,Michael Hansen,James L Januzzi","doi":"10.1002/ejhf.3786","DOIUrl":"https://doi.org/10.1002/ejhf.3786","url":null,"abstract":"AIMSIn individuals with type 2 diabetes with cardio-renal disease but no known heart failure (HF), elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of heart stress, signals higher risk of HF and cardio-kidney complications. This analysis assesses canagliflozin impact on heart stress and outcomes using age-adjusted NT-proBNP thresholds from two major trials.METHODS AND RESULTSThis analysis included 5281 participants from the CANVAS and CREDENCE trials without HF at baseline. NT-proBNP was measured at baseline and year 1, with heart stress defined using age-adjusted NT-proBNP thresholds. Outcomes included a primary composite (end-stage kidney disease, doubling of serum creatinine, kidney or cardiovascular death), kidney composite, HF hospitalization, cardiovascular death, all-cause death, and HF hospitalization or cardiovascular death composite. Multivariable Cox models assessed heart stress, outcomes, and canagliflozin effects. At baseline, 45% of participants had heart stress. Heart stress independently predicted increased risks for all outcomes, with the highest risks in those with persistent or rising NT-proBNP at baseline and year 1. Rising NT-proBNP by year 1 was associated with higher risk as well. Canagliflozin significantly reduced risks in individuals with heart stress, including the primary composite (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.62-0.84), kidney composite (HR 0.65, 95% CI 0.53-0.79), and HF hospitalization (HR 0.68, 95% CI 0.54-0.85). Benefits were less pronounced in those without heart stress.CONCLUSIONSAge-adjusted NT-proBNP thresholds effectively predict cardio-kidney events in at-risk type 2 diabetes individuals without HF. Canagliflozin offers strong cardiovascular and kidney protection, with the greatest benefits in those with heart stress, emphasizing the need for early identification and intervention.CLINICAL TRIAL REGISTRATIONSCANVAS (NCT01032629), CREDENCE (NCT02065791).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"13 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute haemodynamic changes following transcatheter tricuspid valve replacement","authors":"Domenico Angellotti, Joanna Bartkowiak, Daryoush Samim, Lukas Hunziker, Nicolas Brugger, Stephan Windecker, Fabien Praz","doi":"10.1002/ejhf.3781","DOIUrl":"https://doi.org/10.1002/ejhf.3781","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is sodium chloride supplementation ready for clinical practice in acute heart failure? Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study’","authors":"Yohei Masuda, Ichita Yamamoto","doi":"10.1002/ejhf.3765","DOIUrl":"https://doi.org/10.1002/ejhf.3765","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"14 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article 'Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge-to-edge repair'.","authors":"Huayan Li,Minyi Huang,Huazhen Liu","doi":"10.1002/ejhf.3768","DOIUrl":"https://doi.org/10.1002/ejhf.3768","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"7 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology.","authors":"Amina Rakisheva,Dimitrios Farmakis,Andrea Attanasio,Antoni Bayes Genis,Alain Cohen-Solal,Geeta Gulati,Martin Halle,Loreena Hill,Teresa Lopez Fernandez,Alexander R Lyon,Brenda Moura,Ciro Santoro,Carlo Gabriele Tocchetti,Sophie van Linthout,Vassilios Vassiliou,Yusuf Ziya Sener,Makhabbat Bekbosynova,Marco Metra,Giuseppe Rosano,Massimo Piepoli","doi":"10.1002/ejhf.3753","DOIUrl":"https://doi.org/10.1002/ejhf.3753","url":null,"abstract":"Despite advances in cancer treatments with significant improvement in patient outcomes, chemotherapy, targeted molecular therapies and radiotherapy may cause a range of cardiovascular complications, such as cancer therapy-related cardiac dysfunction (CTRCD), which represents a broad spectrum of possible presentation and aetiological link with the broad scope of various cancer therapies, including chemotherapy, targeted agents, immunotherapies, and radiation therapy, aiming at reducing the associated morbidity and mortality. However, practical guidelines on the primary prevention of CTRCD in high-risk patients, a key element in improving prognosis, are lacking in cancer patients and related evidence remains inconclusive. This Clinical Consensus Statement, authored by experts from the Heart Failure Association (HFA) and the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC), and the ESC Council of Cardio-Oncology, aims to discuss the definition and epidemiology of CTRCD, the implicated factors for risk stratification, and the appropriate early diagnostic pathways, while focusing on lifestyle modifications, and pharmacological interventions to reduce the incidence of CTRCD. In addition, a holistic cardio-oncology management approach is advised for prevention and long-term management.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: Insights from EuroTR.","authors":"Daniela Tomasoni,Marianna Adamo,Jörg Hausleiter,Elisa Pezzola,Karl-Patrik Kresoja,Jennifer von Stein,Vera Fortmeier,Christoph Pauschinger,Wolfgang Rottbauer,Mohammad Kassar,Bjoern Goebel,Paolo Denti,Paul Achouh,Tienush Rassaf,Manuel Barreiro-Perez,Peter Boekstegers,Andreas Rück,Monika Zdanyte,Flavien Vincent,Philipp Schlegel,Ralph-Stephan von Bardeleben,Mirjam G Wild,Christian Besler,Stephanie Brunner,Stefan Toggweiler,Julia Grapsa,Tiffany Patterson,Holger Thiele,Tobias Kister,Giuseppe Tarantini,Giulia Masiero,Marco De Carlo,Alessandro Sticchi,Mathias H Konstandin,Eric Van Belle,Tobias Geisler,Rodrigo Estévez-Loureiro,Peter Luedike,Nicole Karam,Francesco Maisano,Philipp Lauten,Fabien Praz,Mirjam Kessler,Daniel Kalbacher,Volker Rudolph,Christos Iliadis,Philipp Lurz,Lukas Stolz,Marco Metra, ","doi":"10.1002/ejhf.3757","DOIUrl":"https://doi.org/10.1002/ejhf.3757","url":null,"abstract":"AIMSTo assess the prevalence, prognostic significance, and predictors of heart failure hospitalization (HFH) before and after tricuspid transcatheter edge-to-edge repair (T-TEER) in a large real-world cohort of patients with tricuspid regurgitation (TR).METHODS AND RESULTSData from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) were analysed. Among 1000 patients undergoing T-TEER for symptomatic TR, 361 (36.1%) had no HFH, 459 (45.9%) had one single HFH, and 180 (18.0%) had multiple HFH the year before T-TEER. Patients with any HFH had more severe heart failure compared with those without. Procedural success (residual TR ≤2) did not differ between patients with single, multiple, or no HFHs before T-TEER. Multivariable analysis showed that a history of HFH was associated with an increased mortality risk (adjusted hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.11-2.06 for single vs. no HFH; adjusted HR 1.63, 95% CI 1.15-2.31 for multiple vs. no HFH), and a higher risk of the combined endpoint of all-cause mortality or HFH. HFH risk decreased by 72% in the 1 year following T-TEER compared to the previous year. Procedural success was the sole independent predictor for reducing HFHs.CONCLUSIONSIn the EuroTR cohort, a history of HFH was highly prevalent and associated with worse clinical outcomes. Among high-risk patients with symptomatic TR, T-TEER significantly lowered HFH risk, with residual TR grade ≤2 being the key predictor for reduced HFH incidence.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"677 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}